30

Sep2015
Report 4: PLA Perspectives, Comparison and Contrast Last week Manulife introduced its new DrugWatch™. It has been described by Manulife as the only program of its kind in Canada which “closely monitors the drug landscape and analyzes the effectiveness and financial impact of new medications, to ensure you receive value ... Read More

17

Sep2015
Report 3: Experience Negotiating Private Payer PLAs PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this survey, which was conducted ... Read More

09

Sep2015
Report 2: Negotiation-Naïve & Interested in Negotiating a Private Payer PLA PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this ... Read More

03

Sep2015
Report 1: Negotiation-Naïve & No Interest in Negotiating a Private Payer PLA PDCI Market Access (PDCI) and H3 Consulting (H3) conducted an online survey of a select group of Canadian pharmaceutical manufacturer and private payer stakeholders to provide clarity on the evolving private payer product listing agreement (PLA) landscape. We thank ... Read More

08

Jun2015
PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were public and private payers, and industry stakeholders in both Canada and Europe. The final issue in this series reveals stakeholder’s perspectives on exclusivity agreements in ... Read More

26

May2015
PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada. The current issue presents the perspectives of stakeholders on the biosimilar market.  Recent experience in Norway ... Read More

19

May2015
PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada.  The current issue presents the perspectives of both private and public payers, and industry representatives ... Read More

14

May2015
PDCI Market Access recently launched the International Trends Series, which provides the results of an online survey PDCI conducted between March 19, 2015 and March 25, 2015. Participants were stakeholders in Europe and Canada.  The first issue, “Delisting of Oncology Treatments” was released last week. This current issue reveals the ... Read More

04

May2015
In preparation for the recent Pharma Symposium conference held in Toronto on March 31-April 1, PDCI conducted an online survey of a select group of pharmaceutical stakeholders in Canada and Europe.  The purpose of this survey was to gauge whether some of the cost containment mechanisms being implemented in certain ... Read More

09

Feb2015
PDCI Market Access Inc. interviewed a representative from one of the pan-Canadian Pharmaceutical Alliance (pCPA) lead provinces and has produced an article providing guidance for negotiating with the pCPA. The pCPA has completed approximately 50 negotiations since it was established in 2010, but stakeholders are still looking for greater transparency ... Read More